化学
药理学
药代动力学
二肽基肽酶-4
作用机理
加药
2型糖尿病
糖尿病
生物化学
医学
内分泌学
体外
作者
Tesfaye Biftu,Ranabir SinhaRoy,Ping Chen,Xiaoxia Qian,Dennis Feng,Jeffrey T. Kuethe,Giovanna Scapin,Ying Duo Gao,Youwei Yan,Davida Krueger,Annette Bak,George J. Eiermann,Jiafang He,Jason M. Cox,Jacqueline D. Hicks,Kathy Lyons,Huaibing He,Gino Salituro,Sharon X. Tong,Sangita B. Patel
摘要
In our effort to discover DPP-4 inhibitors with added benefits over currently commercially available DPP-4 inhibitors, MK-3102 (omarigliptin), was identified as a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excellent pharmacokinetic profile amenable for once-weekly human dosing and selected as a clinical development candidate. This manuscript summarizes the mechanism of action, scientific rationale, medicinal chemistry, pharmacokinetic properties, and human efficacy data for omarigliptin, which is currently in phase 3 clinical development.
科研通智能强力驱动
Strongly Powered by AbleSci AI